Some Epstein-Barr virus (EBV) immune human antisera are known to react with a 142-kDa protein, EBV-encoded nuclear antigen 3 (EBNA3), which, like EBNA1 and EBNA2, is likely to be involved in the establishment of latent infection or growth transformation. We have now constructed gene fusions between Escherichia col lacZ and an EBV DNA open reading frame (BERF1; BamHI E fragment rightward open reading frame 1), which is transcribed into an mRNA in latently infected cells. Purified hybrid protein from one of these constructs, chosen because of its reactivity with EBNA3-positive human antisera, was used to affinity purify the specific antibody from human antiserum. This specific antibody was used to prove that EBNA3 is encoded, at least in part, by BERF1, and that EBNA3 is in the nucleus of each latently infected cell. In rodent cells, BERF1 encodes a 120-to 130-kDa protein, which translocates to the nucleus and is recognized by EBNA3-positive human antisera. Two other proteins similar in size to EBNA3 are detected in latently infected cells by EBV immune human antisera. Two EBV open reading frames related to BERF1 may encode these proteins.
Epstein-Barr virus (EBV) may be an etiologic agent of human lymphoma (1) . Latent EBV infection is prevalent in all human populations (for review, see ref. 2) . The virus readily establishes latency in human B lymphocytes and persists as an episome or by integration into the host genome (3, 4) . Infection of lymphocytes is not completely cryptic in that a highly restricted set of virus genes are regularly expressed and the cell is phenotypically converted to enhanced potential for growth in vitro or in vivo (for review, see ref. 5) . The virus genes expressed in latent infection are presumed to play a role in the enhanced growth potential of latently infected cells or in the maintenance of latent infection.
Two virus-encoded nuclear proteins, EBV nuclear antigens 1 and 2 (EBNA1 and EBNA2), and a virus-encoded cell-membrane protein, the latent membrane protein (LMP), have been definitively identified in latently infected lymphocytes (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) . The evidence that the virus encodes these proteins during latent infection includes the following: (i) Three proteins expressed in bacteria from exons of three latently infected cell mRNAs share epitopes with two nuclear proteins and one membrane protein found in all latently infected cells (7) (8) (9) .
(ii) Exons of each mRNA include nucleotide repeats whose length varies among EBV isolates and correlates with the length of the protein encoded by that isolate in latent infection (7, 10, 11) . (iii) Expression of EBV DNA segments in mammalian cells from eukaryotic expression vectors, which provide for transcription but not translational initiation, results in expression of a full-sized EBNA1 (12) (13) (14) , EBNA2 (15) , or LMP (16) .
Important for the relationship of EBNA1, EBNA2, and LMP with latent infection and growth transformation, has been the demonstration that the respective mRNAs and proteins are expressed in cell lines in which there is no evidence for expression of RNAs or proteins associated with virus replication (17) (18) (19) (20) (21) (22) . Another important criterion has been the demonstration by immunofluorescence that the putative latent protein is present in every latently infected cell (7, 25) . Since genes involved in virus replication are typically expressed in high abundance in a few cells in cloned cell cultures in which most cells are latently infected (22) , early data showed the importance of focusing on cell lines such as IB4 and Namalwa, which can be grown under conditions of tight restriction to latent infection, rather than cell lines such as Raji, which permit early replicative virus gene expression in 0.01-0.1% of the cells (17) (18) (19) (20) (21) . This is particularly important, because early virus replicative cycle genes have previously been mistaken for latent viral genes (23) .
A 142-kDa protein was recently detected in latently infected B lymphocyte nuclei with EBV immune human antisera (24, 25) . Evidence that the protein is a new latent infection viral gene product includes the following: (i) The presence of the protein in not only some (24) but all EBV-infected lymphocyte cell lines, including tightly latently infected Namalwa and IB4 cell lines (25) ; (ii) heterogeneity in the size of the protein in cells infected with different virus isolates (25) ; (iii) lack of reactivity of the protein with antisera against EBNA1, EBNA2, or LMP (25); (iv) presence of a nuclear antigen in all cells of the P3HR-1 cell line by using a serum specific for EBNA3 in these cells (25) ; and (v) the presence of an mRNA encoded by the EBV DNA BamHI E fragment in tightly latently infected 1B4 cells whose function is unknown, but which is sufficiently large to encode a 142-kDa protein (25) . We now prove that this EBV DNA fragment encodes a 142-kDa protein, EBNA3, in all latently infected lymphocytes, and we provide evidence that there may be two additional proteins expressed during latent infection.
MATERIALS AND METHODS
Prokaryotic Expression. The 1.9-kilobase (kb) Pvu II fragment of the EBV DNA BamHI E (26) first rightward long open reading frame (BERF1; see ref. 27 ) was isolated and partially digested with HincII (see Fig. 1 ). The termini were randomized with BAL 31 nuclease and repaired with T4 DNA polymerase. Fragments >300 base pairs (bp) long were ligated with Sma I-cut phosphatase-treated pMC1513 (28) . After transformation of Escherichia coli MC1061, 3-galactosidase-positive colonies were screened for EBV DNA and then for reactivity with an EBV immune human antisera, Abbreviations: EBV, Epstein-Barr virus; EBNA, EBV-encoded nuclear antigen; LMP, latent membrane protein; BERFM, BamHI E fragment rightward open reading frame 1; kb, kilobase(s); bp, base pair(s).
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WC, which has antibody to EBNA3 (25) . The clones were first screened by immunodot blot and then by immunoblot (25) . An E. coli clone containing plasmid pKH27, which expressed a stable 135-kDa immunoreactive fusion protein, was selected. The EBV insert in pKH27 was sequenced directly by the dideoxy method (29) .
Affinity Purification of Antibodies. Late logarithmic-phase bacterial cultures were lysed and hybrid protein was purified by substrate-analog affinity chromatography (30) . Intact fusion protein was further purified by gel exclusion column chromatography using Superose and a FPLC device (Pharmacia). Purified fusion protein (10 mg) was then coupled to trysl-activated Sepharose-4B as described by the manufacturer (Pharmacia). Human serum LP (100 ml) was passed through a column containing the pKH27 fusion protein linked to Sepharose 4B. p-Galactosidase antibody in BamHI/Bgl I fragment (25) (26) (27) was cloned into pZip-Neo-SV(X)1 (31) after T4 DNA polymerase treatment of both the vector and the insert (see Fig. 1 ). The orientation ofthe insert was determined by restriction endonuclease digestion. The resultant recombinant plasmid, pZip-E3 (see Fig. 1 (25) . This RNA is at least partly encoded by the BamHI/Bgl I subfragment of the EBV DNA BamHI E fragment (ref. 25; Fig. 1 ). The important characteristics of this DNA segment (27) (5) .
To determine whether the BERFM open reading frame encodes part of EBNA3, fusions were made between BERFM and the lacZ gene of a prokaryotic expression vector (Fig. 1  A-C) . Three hundred E. coli with various EBV BERF1-iacZ fusions were screened by dot blot for expression of antigens reactive with WC antiserum, an EBNA3 reactive human antiserum. Twelve positive clones were selected and examined by immunoblot analysis. Four clones produced stable immunoreactive fusion proteins of 130-135 kDa. One clone, pKH27, was determined to express a stable 135-kDa fusion protein as at least 1% of total cell protein. The nucleotide sequences of the sites of recombination between EBV DNA and the lacZ gene in pKH27 were determined (Fig. 1D) . The fusion was found to consist, in-frame, of the first seven codons of lacZ, three codons oflinker, codons 538-687 ofthe EBV open reading frame (26) , two codons of linker, and the rest of the lacZ gene.
After removal of /3-galactosidase reactivity, EBNA3-reactive EBV immune human antisera react with the fusion protein; antisera that react only with EBNA1 or EBNA2 do not react with the fusion protein (Fig. 2) . These data are consistent with the working hypothesis that the EBV DNA segment encodes a protein that has EBNA3 epitopes. As a more definitive test, the fusion protein was purified to homogeneity and used in affinity chromatography to determine whether it would specifically select for EBNA3 antibody. Chromatography of EBV immune human antisera on columns containing the fusion protein removed all other reactivity from the human antisera and significantly enriched for antibody against IB4, Namalwa, and Raji EBNA3 (see Figs. 3 and 5) . EBNA3, thus defined, was 142 kDa in IB4 cells, 145 kDa in Namalwa cells, and 137 kDa in Raji cells (Figs. 2 and 3) ; No reactivity was detected to non-EBVinfected B lymphoblast (Louckes) proteins (Figs. 2 and 3) . These data therefore prove that BERFM encodes epitope(s) of EBNA3. Furthermore, only a 142-kDa EBNA3 was detected in immunoblots of B95-8 cell proteins even though some of these cells are permissive of virus replication and produce many of the replicative cycle viral proteins in high abundance (data not shown pZip-El (EBNA1). G418-resistant clones were derived and designated NIH E3, NIH E2, or NIH El, respectively. The EBV-encoded proteins were identified on an immunoblot by using pooled EBNA antiserum, MC antiserum, or pKH27 affinity-purified LP antiserum (AFF). IB4 nuclear proteins are a positive control. NIH 3T3 cells transfected with pZip-NEO-SV(X)1 are a negative control.
tified at least two proteins in IB4 and Namalwa cell extracts in the size range 137-145 kDa, while other human antisera reproducibly recognized only a single protein in immunoblots of the same sample run on the same polyacrylamide gel (25) . For example, WC antiserum consistently recognizes only the EBNA3 protein. This suggests that there is more than one 140-kDa protein in nuclear extracts of IB4 and Namalwa cells. Three EBNA reactive human antisera have been found that react with at least two and probably three different proteins of 142-145 kDa in IB4 cells (Fig. 6A) . The smallest protein in this size range reacts with the pKH27 affinitypurified anti-EBNA3 antiserum (Fig. 6B) , while RY antiserum reacts with EBNA3 as well as a slightly larger 143-kDa protein, tentatively designated EBNA4 (Fig. 6C) . RB antiserum reacts rather specifically with this larger 143-kDa protein, while RS antiserum reacts with an even larger 145-kDa protein, tentatively designated EBNA5 (Fig. 6A) ; MC antiserum reacts with EBNA3 and EBNA4 (Fig. 6B) . The sizes ofthe proteins recognized by these antisera in Namalwa cells were 145, 146, and 147 kDa (Fig. 6C) . Only a 137-and possibly a 138-kDa protein were detected in Raji cells (data not shown).
lymphocytes, there was intense fluorescence over most ofthe nucleus except for discrete patches, which appear to result from nucleolar sparing (Fig. 5) . As expected, the affinitypurified anti-EBNA3 antisera reacted with nuclei of EBNA3-expressing rodent cells, but not with nuclei of EBNA1-or EBNA2-expressing cells (Fig. 5) . The pKH27 affinity-purified and EBNA3-specific antibody detects EBNA3 in all IB4 cells, extending the evidence that EBNA3 is consistently expressed in latent infection ( Fig. 5 ; data not shown).
Other Possible EBNA Proteins. Some human antisera iden- 
DISCUSSION
These data prove that at least part of the EBV BERFM open reading frame is translated into EBNA3. Since this DNA segment encodes a single 4.5-kb RNA in latently infected cells (25) , that RNA is identified as the EBNA3 mRNA. This is the fourth gene proven to be active in latent infection and growth transformation and is therefore designated LT4.
BERFi contains three DNA repeat segments-A, B, and C-of 69, 24, and 66 bp, respectively, arrayed ABCBCACA in the EBV genome (27) . Variation among viral isolates in the number of repeats is probably responsible for the variation in EBNA3 size on NaDodSO4/PAGE. This type of variation is common in EBV proteins (7) (8) (9) (10) (11) Figs. 2 and 3 ). In addition, only a small fraction of the latent viral genome is transcribed into mRNA, making it likely that any unidentified messages come from one of those regions already identified as being transcribed into stable mRNA (25) .
The other salient features of BERF1 are as follows: (i) There are only 12 lysine codons in the 811 codons after the first methionine and none in a run of three basic amino acids as characterizes the nuclear location signals of polyoma or simian virus 40 T proteins (40) . Despite this, the "EBNA3" protein encoded by BERFM in rodent cells localizes to the nucleus. (ii) There is no significant homology to nuclear proteins whose sequence was in the Genbank databank as of January 1985. (iii) There are not two neighboring predicted helical domains similar to the suggested consensus sequence for DNA binding proteins (41) .
The role of EBNA3 in latent infection remains to be defined, as does that of EBNA4 and EBNA5 (should further investigation confirm that these are also encoded by the EBV genome in latent infection). EBNA2 affects the ability of cells to grow in a low level of serum (15) . LMP transforms cells to anchorage independence and tumorigenicity in nude mice (16) . EBNA1 is important in transactivating an EBV "ori"-like sequence for episome maintenance and possibly also for enhancer activation (42) . More than one gene may be involved in the regulation of viral and cellular gene expression in latency. The expression of part or all of EBNA3 in rodent cells may make it possible to define EBNA3 functions in these cells. 
